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Iron delivery by transferrin (Tf) is accomplished
through clathrin-mediated endocytosis of Tf recep-
tors. The small molecule NSC306711 inhibits iron
uptake from the Tf-TfR pathway. Here we show that
the drug’s mechanism of action is to induce internal-
ization and degradation of unoccupied Tf receptors
through an unexpected endocytic pathway. Unlike
classical clathrin-mediated Tf receptor endocytosis,
internalization promoted by NSC306711 is indepen-
dent of clathrin and dynamin, and is sensitive to
the cholesterol-depleting agents filipin and nystatin.
The finding of this cholesterol-dependent Tf receptor
internalization pathway through use of the small-
molecule inhibitor sheds light on the pleiotropic
nature of membrane trafficking dynamics and adds
a complex dimension to our understanding of re-
ceptor regulation. Because of its unusual properties
to inhibit iron uptake, we refer to NSC306711 as
‘‘ferristatin.’’
INTRODUCTION
Iron is an essential nutrient required for DNA synthesis, energy
production, and normal cellular growth. Iron circulates in the
plasma bound to transferrin (Tf) (Hentze et al., 2004). Most cells
express Tf receptors on their surface to bind and internalize Tf
by receptor-mediated endocytosis (Karin and Mintz, 1981;
Klausner et al., 1983b). Elements of Tf-mediated iron delivery
have been exploited to elucidate a mechanistic understanding
of the endocytic process (Conner and Schmid, 2003; Kirchhau-
sen, 2000; Ungewickell and Hinrichsen, 2007). This well-estab-
lished pathway is initiated by the clustering of Tf receptors in
clathrin-coated pits on the plasma membrane and subsequent
internalization by clathrin-coated vesicles. After clathrin coat dis-
assembly, the endocytic vesicles fuse with and transfer their con-
tents to a compartment known as the early endosome. The endo-
some’s acidic environment promotes the release of diferric iron
from Tf. After reduction of Fe3+ to Fe2+, ferrous iron is transported
across the endosomal membrane to the cytosol (Ohgami et al.,
2005), where it may participate in iron-dependent metabolism
(e.g., heme biosynthesis) or become stored for future purpose
(e.g., incorporated into ferritin) (Hentze et al., 2004). After the re-Chemistry & Biology 15lease of iron from Tf, apo-Tf remains bound to the Tf receptor and
returns to the plasma membrane via recycling endosomes. At the
cell surface, apo-Tf dissociates and is released for further rounds
of iron delivery (Dautry-Varsat et al., 1983; Klausner et al., 1983a).
In a screen of the National Cancer Institute’s Diversity Set, we
previously discovered ten small-molecule inhibitors of iron
uptake (Brown et al., 2004). One of these compounds,
NSC306711, was found to block Tf-mediated iron uptake with
IC50 20 mM. Here we show that NSC306711 targets the Tf
receptor by inducing its internalization and degradation. This
activity uncovered an unexpected endocytic pathway for Tf re-
ceptor internalization. Unlike the classical clathrin-mediated en-
docytic pathway, internalization of the Tf receptor induced by
NSC306711 is independent of clathrin and dynamin-1. Instead,
it is sensitive to filipin and nystatin, cholesterol-depleting agents
that disrupt membrane trafficking by lipid rafts. Use of this small-
molecule inhibitor sheds new light on the pleiotropic nature of
membrane trafficking dynamics and adds a complex dimension
to receptor regulation. Because of its unusual properties to
inhibit iron uptake through a cholesterol-dependent pathway,
we refer to NSC306711 as ‘‘ferristatin.’’
RESULTS
Ferristatin Inhibits Endocytosis of Tf
Ferristatin, or NSC306711 (Figure 1A), was found to inhibit iron
transport in an earlier screen for small-molecule inhibitors of
iron uptake (Brown et al., 2004). It is a polyaromatic compound
that contains copper. As shown in Figure 1B, ferristatin not
only blocks 55Fe assimilation but also inhibits internalization of
125I-labeled Tf, suggesting that the drug disrupts Tf internaliza-
tion to acidic endocytic compartments where iron is released
for cellular delivery (Dautry-Varsat et al., 1983; Klausner et al.,
1983a). This idea is supported by fluorescence microscopy ex-
periments showing that HeLa cells treated with ferristatin take
up very little Alexa-red Tf (Figure 1C). Inhibition of Tf internaliza-
tion is not due to a global effect on endocytosis, because uptake
of FITC-dextran and DiI-LDL remain unaffected.
Ferristatin Induces the Degradation of Tf Receptor
To better understand how ferristatin perturbs uptake of Tf, ligand
binding was measured for cells treated with or without ferristatin
for 4 hr at 37C. Specific cell-associated radioactivity was then
determined at 4C using [125I]Tf (Figure 2A). The results of these
experiments demonstrate that the presence of ferristatin does, 647–653, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 647
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Ferristatin Induces Transferrin Receptor Degradationnot interfere with Tf binding to its receptor because without pre-
incubation there was no loss of cell-surface binding in the pres-
ence of the drug compared to control (untreated) cells. However,
the number of receptors on the cell surface was significantly re-
duced after a 4 hr preincubation with ferristatin. Western blot
analysis revealed that after this incubation period, the total
amount of Tf receptor protein was reduced by 60%–70% com-
pared to cells treated with vehicle (DMSO) alone (Figure 2B). In
contrast, LDL receptor levels were not affected, in agreement
with the fluorescence microscopy results for DiI-LDL uptake
(Figure 1D).
To determine the dose response for ferristatin’s effects, west-
ern blot analysis was also carried out on cell lysates obtained af-
ter a 4 hr pretreatment at 37C with increasing concentrations of
the drug (Figure 2C). Loss of Tf receptors was dose dependent
over the same concentration range observed to inhibit [55Fe]Tf
and [125I]Tf uptake (Figure 1B). Identical results were obtained
when the cells were treated with the same concentrations of fer-
ristatin for 24 hr (data not shown). Time-course experiments in-
dicated that >65% of the protein was lost within 4 hr of treatment
with 50 mM ferristatin (Figure 2D). Because the Tf receptor’s half-
life is fairly long (14–18 hr) (Davies et al., 2003; Rutledge et al.,
1991; Ward et al., 1982), the significant reduction in protein levels
over this time frame is most likely due to enhanced receptor deg-
radation rather than reduced biosynthesis. Consistent with this
idea, downregulation of [125I]Tf cell-surface binding in the pres-
ence of ferristatin occurred more rapidly than loss of receptor
protein (Figure 2E). These combined results suggest that ferrista-
tin induces degradation of cell-surface Tf receptors after their in-
ternalization, thereby reducing the number of receptors recycling
back to the cell surface.
Both Lysosomal and Proteasomal Inhibitors Block
Ferristatin-Induced Degradation
To confirm that the loss of Tf receptors arises due to increased
degradation, cells were treated with the lysosomal inhibitors
Figure 1. Inhibition of Tf Uptake by Ferristatin
(A) Structure of ferristatin (NSC306711).
(B) HeLa cells were incubated for 4 hr at 37C in serum-free media containing 40 nM [55Fe]Tf (upper) or [125I]Tf (lower) and the indicated concentrations of ferris-
tatin. After chilling on ice in the presence of unlabeled Tf to displace any surface-bound ligand, cells were washed and then suspended in lysis buffer, and the
amount of [55Fe]Tf or [125I]Tf taken up was determined and normalized to cell protein. Shown are the means (±SEM) from two experiments performed in duplicate
for [55Fe]Tf uptake (n = 4) and in triplicate for [125I]Tf uptake (n = 6). Identical results for [55Fe]Tf uptake were obtained using ferristatin-treated HEK293T cells.
(C) HeLa cells were incubated for 4 hr at 37C with or without 50 mM ferristatin, and then Alexa-red Tf, FITC-dextran, or DiI-LDL were added to the cells for an
additional 20 min incubation. The cells were then placed on ice, rinsed, and fixed with 4% paraformaldehyde and mounted. Cells were examined by fluorescence
microscopy (Nikon Eclipse E600, Zeiss) at a nominal magnification of 603. Digital images were taken using a Spot Slider camera and Spot Advance software (RT
Diagnostics).648 Chemistry & Biology 15, 647–653, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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Ferristatin Induces Transferrin Receptor DegradationFigure 2. Ferristatin Induces the Degradation of Tf Receptor
(A) HeLa cells were incubated for 4 hr at 37C with or without 50 mM ferristatin, and then both sets of cells were further incubated for 2 hr on ice with 50 mM
ferristatin and 500 nM [125I]Tf in the presence or absence of 5 mM unlabeled Tf. After washing, cell-associated radioactivity was determined, and the difference
measured in the presence and absence of unlabeled Tf was calculated as specific cell-surface binding and normalized to control (treated with vehicle alone). The
average of duplicate values is shown; similar results were obtained on three different occasions.
(B) HeLa cells were treated with or without 50 mM ferristatin for 4 hr at 37C and cell lysates were prepared and electrophoresed on a 7.5% SDS-polyacrylamide
gel. After transfer to nitrocellulose, immunoblotting was used to detect Tf receptor (top) or LDL receptor (middle) levels as described in the Experimental
Procedures. Actin was also immunoblotted as a loading control (bottom).
(C) HeLa cells were incubated for 4 hr with increasing concentrations of ferristatin as shown. After washing, cell lysates were prepared and immunoblotted for Tf
receptor levels.
(D) HeLa cells were treated with 50 mM ferristatin for the indicated times, and then lysates were prepared and immunoblotted to determine Tf receptor levels.
(E) HeLa cells were treated with or without 50 mM ferristatin at 37C for the indicated times. Cell-surface [125I]Tf binding was determined as described for (A). The
average of duplicate values is shown; similar results were obtained on three different occasions.bafilomycin A1, leupeptin, or chymostatin, and then further incu-
bated with or without ferristatin. Ferristatin-induced Tf receptor
degradation was blocked by each of these three inhibitors
(Figure 3A). Cells were also treated with two proteasome inhibi-
tors, epoxomicin and MG132, prior to incubation with ferristatin.
Cells treated with the proteasome inhibitors were also resistant
to ferristatin-induced receptor degradation (Figure 3B). Thus,
both lysosomal and proteosomal pathways appear to play
a role in ferristatin-induced receptor degradation. To determine
whether lysosome or proteasome inhibition interfered with inter-
nalization of Tf receptors, cells were again treated with chymos-
tatin (to inhibit lysosomal protease activity) or epoxomicin (to
block proteasomal activity), and then incubated with or without
ferristatin and assayed for surface [125I]Tf binding. The amount
of Tf bound to the cell surface was reduced even though ferrista-
tin-induced Tf receptor degradation was blocked by both inhib-
itors (Figures 3C and 3D). These combined observations indicate
that steps sensitive to both lysosomal and proteosomal inhibi-
tors occur after the receptor is internalized.Chemistry & Biology 1Characterization of Tf Receptor Trafficking in the
Presence of Ferristatin
To explore whether Tf receptor internalization in the presence of
ferristatin occurs by the classical clathrin-mediated endocytic
pathway, we used siRNA to knock down clathrin expression
(Huang et al., 2004). Fluorescence microscopy confirmed the re-
duction of clathrin levels in siRNA-treated cells and showed that
uptake of Alexa-red Tf by HeLa cells was blocked, with pro-
nounced surface staining observed in comparison to vehicle
control (Figure 4A). However, in the presence of ferristatin, Tf
receptors were still lost from these cells, with little Alexa-red Tf
staining observed. Thus, the Tf receptor is internalized and
becomes degraded in the presence of ferristatin by a clathrin-
independent mechanism.
Dynamin is a GTPase known to participate in clathrin-mediated
endocytosis (Conner and Schmid, 2003; Kirchhausen, 2000;
Ungewickell and Hinrichsen, 2007). To study its role, cells were
transfected with either wild-type (WT) or the dominant-negative
K44A mutant of dynamin-1. Seventeen hours posttransfection,5, 647–653, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 649
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Ferristatin Induces Transferrin Receptor Degradationcells were treated with ferristatin and then incubated with
Alexa-red Tf. Figure 4B shows that uptake of Alexa-red Tf
was blocked, with most surface staining observed in cells trans-
fected with the dominant-negative dynamin mutant; however, in
the presence of ferristatin, very little Alexa-red Tf staining was
observed, indicating that Tf receptors were lost from cells trans-
fected with wild-type as well as the K44A mutant. The fact that
loss of Tf receptors occurred in the presence of the dominant-
negative mutant suggests that dynamin is not involved in the
ferristatin-induced internalization pathway.
Alternate pathways for endocytic uptake that are independent
of clathrin and dynamin involve lipid rafts and are known to be
sensitive to cholesterol depletion (Brown, 2006; Kirkham and
Parton, 2005; Parton and Richards, 2003). Therefore, the effects
of filipin and nystatin, two cholesterol-binding agents, were stud-
ied. Western blot analysis showed that Tf receptor degradation
induced by ferristatin was blocked by cholesterol depletion
(Figure 5A). This effect correlated with the ability of nystatin to
block the internalization of Tf receptors in the presence of ferris-
tatin, as measured by cell-surface [125I]Tf binding (Figure 5B).
Ferristatin did not appear to have more generalized effects on
the lipid raft endocytic pathway, because trafficking of cholera
toxin subunit B was unaffected (Figure 5C). This nontoxic subunit
enters cells by binding to the lipid raft ganglioside GM1 (Miller
Figure 3. Lysosomal and Proteasomal
Inhibitors Block Ferristatin-Induced Tf
Receptor Degradation
(A) HeLa cells were treated overnight with the lyso-
somal inhibitors bafilomycin A1 (100 nM), leupeptin
(90 mg/ml), or chymostatin (10 mg/ml).
(B) HeLa cells were treated overnight with the
proteasomal inhibitors epoxomicin (100 nM) and
MG132 (20 mM). After preincubation with these
inhibitors, the cells were washed and further incu-
bated in fresh serum-free medium with or without
the inhibitors and with or without 50 mM ferristatin
as indicated. After a 4 hr incubation, cells were
washed and lysed and the samples were immuno-
blotted to detect Tf receptor. Actin levels were
also determined as a loading control. Immuno-
blots detecting p27 levels as a positive control
for proteasome inhibition are included.
(C and D) HeLa cells were pretreated overnight
with 100 nM epoxomicin (C) or 10 mg/ml chymos-
tatin (D) and then further treated with or without
50 mM ferristatin for 4 hr as indicated. Cells were
placed on ice and incubated for 2 hr with 500 nM
[125I]Tf in the presence or absence of 5 mM unla-
beled Tf. After washing, cell-associated radio-
activity was determined, and the difference mea-
sured in the presence and absence of unlabeled
Tf was calculated. The average of duplicate values
is shown; similar results were obtained on two dif-
ferent occasions. Cell lysates were also immuno-
blotted to determine Tf receptor levels (insets).
et al., 2004). Furthermore, ferristatin did
not alter the stability of flotillin, a resident
of the lipid raft pathway (Bickel et al.,
1997), as shown by western blot analysis
(Figure 5D). Because nystatin-sensitive
endocytosis has been implicated in some investigations to
involve the actin cytoskeleton (Chichili and Rodgers, 2007;
Kirkham and Parton, 2005; Parton and Richards, 2003), the influ-
ence of cytochalasin B, latrunculin A, and jasplakinolide were
studied. Cell-surface ligand binding and western blot analysis
showed that none of these actin inhibitors blocked ferristatin-
induced Tf receptor internalization or degradation (see Figure
S1 available online).
DISCUSSION
As a small-molecule inhibitor, ferristatin (NSC306711) was pre-
viously shown to block iron assimilation from Tf (Brown et al.,
2004). The results reported here reveal that ferristatin targets
this pathway by inducing the internalization and subsequent
degradation of cell-surface Tf receptors. Our characterization
of ferristatin’s mechanism of action has yielded insights about
Tf receptor regulation and trafficking. Ferristatin appears to
enhance endocytosis of Tf receptors by nystatin-sensitive in-
ternalization via lipid rafts. The fact that its activity is indepen-
dent of clathrin and dynamin supports the idea that this alter-
native pathway is induced by ferristatin to mediate receptor
endocytosis.650 Chemistry & Biology 15, 647–653, July 21, 2008 ª2008 Elsevier Ltd All rights reserved
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Ferristatin Induces Transferrin Receptor DegradationElements of Tf receptor endocytosis are well characterized
(Karin and Mintz, 1981; Klausner et al., 1983a, 1983b; Dautry-
Varsat et al., 1983), including functions associated with coated
vesicle biogenesis involving clathrin and dynamin (Conner and
Schmid, 2003; Kirchhausen, 2000; Ungewickell and Hinrichsen,
2007). Unfortunately, few studies have explored alternative path-
ways for Tf receptor trafficking that are known to regulate recep-
tor uptake in other systems. For example, high concentrations of
epidermal growth factor (EGF) promote internalization of its re-
ceptor through a clathrin-independent pathway involving lipid
rafts; this pathway has also been shown to enhance degradation
of the EGF receptor (Sigismund et al., 2005). Such alternative en-
docytic pathways can have important regulatory functions. For
example, the insulin-regulated glucose transporter GLUT4 is
internalized via a nystatin-sensitive pathway that is blocked by
insulin (Blot and McGraw, 2006). The transforming growth factor
b superfamily also utilizes two distinct endocytic pathways for
different receptor functions. Internalization through the clathrin-
dependent pathway promotes cell signaling whereas receptor
uptake via lipid rafts regulates receptor turnover (Di Guglielmo
Figure 4. Ferristatin-Induced Tf Receptor
Degradation Is Clathrin and Dynamin
Independent
(A) HeLa cells were transfected with siRNA to
knock down expression of clathrin as described
in the Experimental Procedures. After incubation
with 50 mM ferristatin for 4 hr at 37C, Alexa-red
Tf (5 mg/ml) was added for an additional 10 min.
The cells were then rinsed with ice-cold PBS
and fixed with 4% paraformaldehyde. After per-
meabilization with 0.1% Triton X-100, the cells
were immunostained with a monoclonal anti-
clathrin antibody (X22) and a secondary goat
anti-mouse antibody conjugated to Alexa Fluor
488.
(B) HeLa cells were transfected with either wild-
type (WT) or the dominant-negative K44A mutant
of dynamin-1. After a 4 hr incubation with 50 mM
ferristatin, Alexa-red Tf (5 mg/ml) was added to
the cells for 20 min to monitor Tf uptake. The cells
were then washed, fixed, and immunostained with
mouse anti-dynamin antibody (Hudy1) using an
Alexa Fluor 488-conjugated secondary antibody
as described above. Cells were examined by con-
focal microscopy on a Nikon TE2000 inverted microscope at a nominal magnification of 1003. Digital images were taken using an Orca ER cooled CCD camera
(Hamamatsu Photonics) and processed using Slidebook software (Intelligent Imaging Innovations).
Figure 5. Internalization of Tf Receptors is
Sensitive to Cholesterol Depletion
(A) HeLa cells were pretreated for 30 min with
5 mg/ml filipin or 25 mg/ml nystatin or left untreated.
After incubation with 50 mM ferristatin for 4 hr, cell
lysates were prepared and electrophoresed for
immunoblotting to detect Tf receptor (upper) or
actin (lower).
(B) HeLa cells were pretreated for 30 min with
25 mg/ml nystatin and then further treated with or
without 50 mM ferristatin for 4 hr as indicated. Cells
were placed on ice and incubated for 2 hr with
500 nM [125I]Tf in the presence or absence of 5 mM
unlabeled Tf. After washing, cell-associated radio-
activity was determined, and the difference mea-
sured in the presence and absence of unlabeled
Tf was calculated. The average of duplicate values
is shown; similar results were obtained on two dif-
ferent occasions. Cell lysates were also immuno-
blotted to determine Tf receptor levels (inset).
(C) HeLa cells were incubated for 4 hr at 37C with
or without 50 mM ferristatin, and then Alexa Fluor 488 cholera toxin subunit B was added to the cells for an additional 30 min incubation. The cells were then placed
on ice, rinsed, and fixed with 4% paraformaldehyde and mounted. Cells were examined by fluorescence microscopy using a Zeiss Axiotome microscope equip-
ped with Axiovision software at a nominal magnification of 603.
(D) HeLa cells were treated with or without 50 mM ferristatin for 4 hr at 37C and cell lysates were prepared and electrophoresed on a 7.5% SDS-polyacrylamide
gel. After transfer to nitrocellulose, immunoblotting was used to detect Tf receptor (top) or flotillin (middle) levels as described in the Experimental Procedures.
Actin was also immunoblotted as a loading control (bottom).Chemistry & Biology 15, 647–653, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 651
Chemistry & Biology
Ferristatin Induces Transferrin Receptor Degradationet al., 2003). Through the use of the small-molecule inhibitor
ferristatin, we have shown that lipid rafts can also mediate inter-
nalization of Tf receptors, and that this pathway is associated
with receptor degradation.
Our study further shows that ferristatin-induced Tf receptor
downregulation by the lipid raft pathway is associated with deg-
radative loss of the receptor in a step that is sensitive to both pro-
teasomal and lysosomal inhibitors. Neither of these inhibitors
blocks receptor internalization, an observation that indicates en-
docytosis occurs independently of these functions. Our studies
implicate a role for the proteosome in membrane protein degra-
dation that is unexpected, particularly as Tf receptors are
thought to be degraded by the lysosome (Rutledge et al.,
1991). Although it is possible that ubiquitinylation of the Tf recep-
tor itself could be involved in this process, we have not been able
to detect this protein modification on the receptor (our unpub-
lished observations). One speculation is that upon lipid raft
internalization of Tf receptors, ferristatin’s action promotes the
proteasomal degradation of a factor that would otherwise pre-
vent trafficking of receptors to the lysosome in the lipid raft endo-
cytic pathway. However, other explanations for the influence of
both proteosomal and lysosomal inhibitors cannot be excluded,
and it is possible that ferristatin has multiple cellular effects. In
fact, we have found that it disrupts non-Tf-bound iron uptake
as well as the Tf-mediated delivery of iron; how these observa-
tions may be related remains unknown. Future use of the
small-molecule inhibitor ferristatin should provide new insights
about membrane trafficking of Tf receptors and its regulation,
as well as the necessary means to identify new factors involved
in iron transport.
SIGNIFICANCE
Iron is an essential nutrient required for DNA synthesis, en-
ergy production, and normal cellular growth. Iron circulates
in the plasma bound to transferrin (Tf) (Hentze et al., 2004).
Most cells express Tf receptors on their surface to bind
and internalize Tf by receptor-mediated endocytosis (Karin
and Mintz, 1981; Klausner et al., 1983b). Elements of Tf-me-
diated iron delivery have been exploited to elucidate a mech-
anistic understanding of the endocytic process (Conner and
Schmid, 2003; Kirchhausen, 2000; Ungewickell and Hinrich-
sen, 2007). Using a chemical genetics approach, we have
previously established that the small-molecule inhibitor fer-
ristatin (NSC306711) blocks iron assimilation from Tf (Brown
et al., 2004). Here we show that the drug’s mechanism of
action is to induce internalization and degradation of Tf re-
ceptors through an unexpected endocytic pathway. Unlike
classical clathrin-mediated Tf receptor endocytosis, inter-
nalization promoted by ferristatin is independent of clathrin
and dynamin, and is sensitive to the cholesterol-depleting
agents filipin and nystatin. After nystatin-sensitive internali-
zation, ferristatin-induced Tf receptor degradation is
blocked by inhibitors of both the proteasome and lysosome.
One plausible explanation for these observations is that fer-
ristatin promotes degradation of a factor associated with
intracellular Tf receptor trafficking by the proteosome,
thereby releasing internalized receptors to the lysosomal
degradative pathway. Regardless of how intracellular deg-652 Chemistry & Biology 15, 647–653, July 21, 2008 ª2008 Elsevierradation occurs, the nystatin-sensitive degradation of Tf
receptors induced by ferristatin ultimately accounts for its
ability to block Tf-mediated iron uptake. The discovery of
this novel cholesterol-dependent Tf receptor internalization
pathway through use of the inhibitor demonstrates the utility
of small molecules in the study of complex cellular
processes.
EXPERIMENTAL PROCEDURES
Cell-Culture and Transfection Conditions
HeLa cells were grown in Dulbecco’s minimal essential medium (DMEM) con-
taining 50 U/ml penicillin, 50 mg/ml streptomycin, and 10% fetal bovine serum
(FBS). Cells were treated with ferristatin in serum-free DMEM. Cells were tran-
siently transfected to express wild-type or K44A mutant dynamin-1 with plas-
mids kindly provided by Sanja Sever (Massachusetts General Hospital) using
LipofectAMINE 2000 (Invitrogen) according to the manufacturers’ instructions.
Cells were transfected with siRNA duplexes against the clathrin heavy chain
(Dharmacon) as described by Huang et al. (2004). Briefly, subconfluent HeLa
cells were transfected twice with 20 mM siRNA duplex (day 1 and day 2) and
then placed in fresh DMEM supplemented with 10% FBS for 14 hr prior to
experiments, which were performed on day 3.
Transferrin Uptake and Binding Assays
Prior to Tf uptake assays, HeLa cells were washed with phosphate-buffered
saline containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS++) and then incubated
for 4 hr at 37C with [125I]Tf in PBS++, with or without 50 mM ferristatin. As
a control, cells were incubated with vehicle alone (0.5% DMSO). To quench
uptake, cells were chilled on ice, washed with ice-cold PBS++, and incubated
with 500 nM unlabeled Tf for 1 hr at 4C to displace any surface-bound radio-
activity. After washing with ice-cold PBS++, cells were lysed with 0.1% Triton
X-100 containing 0.1% NaOH, and cell-associated radioactivity and protein
levels were determined. Uptake, calculated as pmol [55Fe]Tf or [125I]Tf/mg
cell protein, was normalized to control (vehicle alone). Cell-surface Tf binding
was determined in a similar fashion, except that HeLa cells were treated with or
without ferristatin, washed in ice-cold PBS++, and then incubated on ice for 2
hr with 500 nM [125I]Tf in the presence or absence of 5 mM unlabeled Tf. At the
end of incubation the cells were washed and solubilized, and surface-bound
radioactivity was measured by gamma counting. Specific binding was calcu-
lated as the difference in cell-associated radioactivity displaced by unlabeled
Tf, normalized to cell protein.
Fluorescence Microscopy
HeLa cells were treated with 50 mM ferristatin or vehicle control (0.5% DMSO)
for 4 hr and then incubated with 5 mg/ml Alexa Fluor 594 Tf (Alexa-red Tf; Invi-
trogen), 25 mg/ml FITC-dextran, or 20 mg/ml DiI-LDL for an additional 20 min, or
with 40 nM Alexa Fluor 488 cholera toxin subunit B (Invitrogen) for an additional
30 min. Cells were washed with PBS++ and fixed with 4% paraformaldehyde.
For dynamin and clathrin staining, fixed cells were permeabilized with 0.1%
Triton X-100 and rinsed with 1% NH4Cl in PBS. The cells were then blocked
with 5% goat serum and immunoreacted with mouse anti-dynamin (1:200; Up-
state) or mouse anti-clathrin (1:100; Santa Cruz Biotechnology) in PBS con-
taining 2% goat serum and a secondary goat anti-mouse conjugated to Alexa
Fluor 488 (1:400; Invitrogen) for 40 min. Cells were washed with PBS++ and
fixed with 4% paraformaldehyde. After copious rinsing with PBS, cells were
briefly dried and coverslips were mounted using fluorescent mounting medium
(DakoCytomation).
Western Blot Analysis
To determine the effects of ferristatin on Tf receptor levels, HeLa cells were
washed three times with PBS++ and lysed in NET lysis buffer (150 mM
NaCl, 5 mM EDTA, 10 mM Tris [pH 7.4], 1% Triton X-100). The cells lysates
were spun at 14,000 rpm for 10 min and 50 mg of the supernatant was loaded
on 7.5% SDS-polyacrylamide gels. After electrophoresis, samples were trans-
ferred to nitrocellulose for immunoblotting using a monoclonal anti-human Tf
receptor antibody (1:1000; Zymed), a monoclonal anti-human LDL receptor
antibody (1:2000; a kind gift of Monty Krieger, Massachusetts Institute ofLtd All rights reserved
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Ferristatin Induces Transferrin Receptor DegradationTechnology), or a monoclonal anti-flotillin-1 antibody (1:500; BD Biosciences).
As a loading control, blots were also probed with mouse anti-actin (1:12,000;
ICN). Secondary IRDye800-conjugated goat anti-mouse (1:10,000; Rockland)
was used to detect immunoreactivity using an Odyssey Infrared Imaging
System (LI-COR). Relative intensities of protein bands normalized to actin
were determined using Odyssey version 1.2 software.
SUPPLEMENTAL DATA
Supplemental Data include one figure and can be found with this article online
at http://www.chembiol.com/cgi/content/full/15/7/647/DC1/.
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